Half-year report · HY
4886.TEDINET S100WZ8Y
Period2025-04-01 → 2025-09-30
Filed2025-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥35.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥64.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥32.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥2.6bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.7bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.8bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.4bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥108.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥103.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥88.3bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥36.2bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥32.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥72.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥71.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥64.2bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.1bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥78.49 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.95 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.36 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 61.5% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥141m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥99m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥15m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥42m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥42m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥870m |
| Animal Health Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Animal Health Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Animal Health Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥282m |
| Oversea Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Oversea Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Oversea Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥132m |
| Pharmaceutical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥29.3bn |
| Pharmaceutical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥29.3bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥35.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥35.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥42m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥151m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥113m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| Animal Health Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Animal Health Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Animal Health Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥177m |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 488
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in treasury stock fin cf | InterimDuration | -0 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -566000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -850000000 | JPY |
| Other net fin cf | Prior1InterimDuration | － | JPY |
| Other net fin cf | InterimDuration | -13000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -2406000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | 1382000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -3000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -68000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -3033000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -3540000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 16738000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 10603000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 13705000000 | JPY |
| Cash and cash equivalents | InterimInstant | 7062000000 | JPY |
| Salaries allowances and bonuses sga | Prior1InterimDuration | 1746000000 | JPY |
| Salaries allowances and bonuses sga | InterimDuration | 1934000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1InterimDuration | － | JPY |
| Provision of allowance for doubtful accounts sga | InterimDuration | -6000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 807000000 | JPY |
| Provision for bonuses sga | InterimDuration | 835000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 144000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 148000000 | JPY |
| Transportation warehousing expenses sga | Prior1InterimDuration | 3209000000 | JPY |
| Transportation warehousing expenses sga | InterimDuration | 3306000000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 3093000000 | JPY |
| Research and development expenses sga | InterimDuration | 3703000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 28617000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E35791-000AnimalHealthBusinessReportableSegmentsMember | 3640000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 113000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 32371000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 32371000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E35791-000AnimalHealthBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 38000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 38000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -38000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 28617000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E35791-000AnimalHealthBusinessReportableSegmentsMember | 3640000000 | JPY |
| Net sales | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 151000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 32409000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -38000000 | JPY |
| Net sales | Prior1InterimDuration | 32371000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 3825000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E35791-000AnimalHealthBusinessReportableSegmentsMember | 177000000 | JPY |
| Operating income | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -4000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3998000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -652000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |